Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

BACKGROUND: Quizartinib, an inhibitor of class III receptor tyrosine kinases (RTKs), is currently in phase 3 development for the treatment of acute myeloid leukemia (AML) bearing internal tandem duplications in the FLT3 gene. Aberrant RTK signaling is implicated in the pathogenesis of a variety of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadopoulos, Kyriakos P., Ben-Ami, Eytan, Patnaik, Amita, Trone, Denise, Li, Jianke, Demetri, George D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080548/
https://www.ncbi.nlm.nih.gov/pubmed/30081867
http://dx.doi.org/10.1186/s12885-018-4692-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080548/
https://www.ncbi.nlm.nih.gov/pubmed/30081867
http://dx.doi.org/10.1186/s12885-018-4692-z

Ejemplares similares